Neurimmune to Present Key Advances in Treating Protein Aggregation Diseases at AD/PD 2026
Neurimmune today announced its participation in the upcoming 20th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD 2026) in Copenhagen, Denmark, from March 17 to March 21, 2026.
As part of the company’s commitment to advancing neurodegenerative disease research, Dr. Peter C. Kahr, VP Clinical Development, will present pioneering work in depleting misfolded proteins for the treatment of human diseases. Prof. Angela Genge, CMO of AL-S Pharma, a spin-out company of Neurimmune, will present Phase 2 data from AP-101, a first-in-class antibody targeting misfolded SOD1 for the treatment of amytrohpic lateral sclerosis.
Presentation Details:
Title: Depleting Pathogenic Protein Aggregates in Human Diseases (ID3322)
Date: March 21, 2026, 09:40 - 09:55, Auditorium 11
Presenter: Dr. Peter C. Kahr
-
Title: Phase 2 Biomarker and Clinical Results of AP-101, a Human Antibody Targeting Misfolded SOD1 in Amyotrophic Lateral Sclerosis (ID 3352)
Date: March 19, 2026, 08:40 - 08:55, Hall A2
Presenter: Prof. Dr. Angela Genge
Neurimmune proudly supports the dissemination of cutting-edge scientific knowledge and fostering collaboration across academia, industry and clinical communities by an educational grant in recognition of Donald L. Price (1935-2023). Don Price was an extraordinary leader in the fields of clinical and experimental neuropathology and a professor at the John Hopkins School of Medicine.
Don Price Memorial Lecture:
Title: Five Critical Inflection Points in Alzheimer’s: Guideposts for Smarter Drug Development
Date: March 18, 2026, 08:00–08:30, Hall A1
Presenter: Prof. Bart De Strooper
“ADPD presents a unique platform to foster collaboration and share the latest innnovation in neurodegenerative disease research and clinical development,” said Dr. Jan Grimm, CSO of Neurimmune. “We are honored to contribute to this important meeting and to present our progress towards developing transformative therapies for the treatment of protein aggregation diseases.”
For more information, please visit adpd.kenes.com
About Neurimmune
Neurimmune is a clinical-stage biopharmaceutical company building next generation antibody therapeutics. The company pioneers amyloid depletion as a novel therapeutic mechanism to treat CNS and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis and ATTR cardiomyopathy. Neurimmune discovered the anti-ATTR antibody cliramitug (formerly NI006, ALXN2220, Phase 3) for ATTR cardiomyopathy, the anti-misfolded SOD1 antibody AP-101 (Phase 2) for ALS, the anti-NogoA antibody NG004 (Phase 1) for spinal cord injury and the anti-amyloid light chain antibody NI009 (preclinical) for AL amyloidosis.
About AL-S Pharma AG
AL-S Pharma is a clinical-stage biotech company developing AP-101 for the treatment of amyotrophic lateral sclerosis (ALS). Founded and co-owned by Neurimmune and TVM Capital Life Science, AL-S Pharma brings together a seasoned team of biotech and pharmaceutical leaders with expertise spanning drug discovery, translational research, and clinical development. AL-S Pharma is based in Zurich, Switzerland. For more information, visit www.al-spharma.com.
Contact for Media
Martin Meier-Pfister (Switzerland)
media@neurimmune.com